PCSK9 Inhibitors: Preliminary New Evidence Update
This Preliminary New Evidence Update for PCSK9 inhibitor alirocumab (Praluent®, Regeneron/Sanofi) incorporates results from the ODYSSEY outcomes trial presented at the American College of Cardiology’s 2018 Scientific Session. Under ICER’s established protocols for accepting in-confidence data, an agreement with Regeneron and Sanofi allowed ICER to evaluate the new evidence and, working with a team of academic faculty from the University of California, San Francisco, to update its cost-effectiveness analyses and associated value-based price benchmarks for this drug.
Given these new outcomes data confirming a mortality benefit for alirocumab, ICER is issuing this preliminary update to help inform new pricing and coverage negotiations between manufacturers and payers. We plan to issue a final New Evidence Update for alirocumab by May 3, 2018, following the methodology and procedures defined on our website.View All Materials on this Topic or Go Back to View More Materials